Replacing one class of cholesterol lowering drugs with another is pure stupidity. They aren't even addressing the correct problem. Inflammation! If there was no inflammation it wouldn't grab the cholesterol out of the bloodstream and pack it into plaque. Do these people never read research? Or understand anything about cause and effect? Leaders would tackle the hardest problems. Alas, we have no leaders in stroke. Kiss your neurons goodbye if you have a stroke.
Statins cause enough problems without going to a new drug that might rarely cause
neurocognitive problems.
You can see a video of how plaque forms here:
Inflammation In Atherosclerotic Plaque Formation
Experimental cholesterol drugs cut heart risk, but questions remain
Studies of a new class of experimental cholesterol-lowering drugs signal that they may reduce by half the risk of heart attack and other major cardiovascular problems compared to standard treatment alone.
Doctors at the annual meeting of the American College of
Cardiology, where the studies were presented, called the results
"encouraging," but said larger, controlled trials were needed to fully
understand the drugs, known as PCSK9 inhibitors.
An analysis of about 4,500 patients who continued
treatment for nearly a year after completing earlier trials of Amgen
Inc's Repatha, also known as evolocumab, found that 0.95 percent of
patients given the drug and standard therapy suffered a cardiovascular
event, compared with 2.18 percent of the group receiving standard
treatment, which ranged from dietary changes to drugs such as statins.
Amgen defined "event" in the study as death, heart attack,
stroke or "mini-stroke," unstable chest pain or heart failure requiring
hospitalization, or the need for a procedure to restore bloodflow to
the heart.
Side
effects more frequent, but still rare, in patients treated with Repatha
included neurocognitive problems - something the U.S. Food and Drug
Administration has said should be monitored closely.
More at link.
No comments:
Post a Comment